KOSDAQBiotech & Pharma179530

Adbiotech

₩552▼ 8.76%2026-11-18 close
Market Cap
₩17.2B
Turnover
₩500M
Volume
850K
Shares out.
31.1M
PER
—
PBR
—
EPS
-₩29
Dividend Yield
0.00%

PER, EPS, PBR and BPS are calculated in-house from the last 4 quarters (2025Q4–2026Q3) · Dividend yield is based on ₩0 per share · Prices as of the 2026-11-18 close

01

Report overview

Narrowing losses as Adbiotech widens into bio and pet healthcare

Adbiotech grew revenue and narrowed its operating loss in 2025, but it has posted net losses attributable to controlling shareholders for three straight years while widening into bio and pet healthcare.

  1. 1

    2025 revenue rose 15.8% year on year to KRW 12.9 billion, the second straight annual increase after 2023's low.

  2. 2

    The operating loss narrowed from KRW 4.94 billion in 2022 to KRW 3.5 billion in 2025, though the company has been loss-making for four straight years. The 2025 operating margin was -27.1%.

  3. 3

    Q3 2026 revenue reached KRW 7.15 billion, up 97.3% year on year, with an operating loss of KRW 1.16 billion. The company has booked operating losses for three consecutive quarters since Q1 2026.

  4. 4

    An August 2026 rights-style third-party share issue brought in KRW 13.3 billion, alongside a KRW 3.0 billion tenth convertible bond issued to the largest shareholder's fund. The debt-to-equity ratio fell from 675.6% in 2024 to 257.5% in 2025.

  5. 5

    The company added medical and pharmaceutical R&D, contract manufacturing and clinical consulting, and pet healthcare to its business purposes. Its joint development with a U.S. biotech partner remains at an early, preclinical stage.

02

Business structure

Adbiotech is a bio company founded in 2000 that develops and manufactures animal drugs and feed supplements to replace vaccines and antibiotics, built on three antibody platforms: IgY, VHH (nanobody) and scFv.

According to Butler's data for Q2 2026, the revenue mix was animal medicines 56%, feed supplements 24%, merchandise 14% and other products 6%.

Its core customers are livestock farms and public procurement demand, and the company attributed the 2025 revenue increase to export sales from overseas orders and higher sales to the Public Procurement Service. The pipeline includes antibodies against porcine PRRS, shrimp EMS and WSSV, and avian influenza.

In pet healthcare, the company produces and supplies single-use artificial tear products for companion animals in Korea and has completed FDA food facility registration in the United States.

In May 2026 it proposed adding medical and pharmaceutical R&D, contract manufacturing, clinical consulting and pet healthcare to its business purposes, and in August 2026 a shareholder meeting approved four new directors as proposed.

In July 2026 it acquired a 12.28% stake in pet healthcare company Onheal for about KRW 10 billion. Animal medicine competition in Korea involves roughly 1,100 companies, so product differentiation and distribution matter.

03

Earnings trend

Quarterly revenue · Operating profit
RevenueOperating profit
Annual revenue · Operating profit
RevenueOperating profit
Quarterly results · Last 5 quarters
QuarterRevenueOperating profitOp. margin
2025Q3₩3.6B-₩1.8B−48.5%
2025Q4₩3B₩300M11.6%
2026Q1₩3.1B-₩1.1B−34.6%
2026Q2₩2.9B-₩1.9B−66.6%
2026Q3₩7.2B-₩1.2B−16.2%
Annual results
YearRevenueOperating profitNet income (parent)Op. marginROEDebt-to-equity
2022₩10.6B-₩4.9B₩2.7B−46.4%16.7%91.6%
2023₩10.5B-₩4.8B-₩2.9B−45.5%−21.4%159.0%
2024₩11.1B-₩4.1B-₩8B−37.0%−164.4%675.6%
2025₩12.9B-₩3.5B-₩3.3B−27.1%−21.6%257.5%

Consolidated basis (financial statements including subsidiaries) · Final figures from DART filings · Net income attributable to owners of the parent · Data as of 2026-11-18

04

Earnings analysis

Annual revenue went from KRW 10.6 billion in 2022 to KRW 10.5 billion in 2023 (down 1.5% year on year), then KRW 11.1 billion in 2024 (up 6.3%) and KRW 12.9 billion in 2025 (up 15.8%).

Revenue has grown for two consecutive years, from 2024 through 2025, and 2025 is the largest year in the 2022 to 2025 span, while 2023 is the smallest.

The operating loss went from KRW 4.94 billion in 2022 to KRW 4.76 billion in 2023, KRW 4.12 billion in 2024 and KRW 3.5 billion in 2025, so losses narrowed each year and the company has been loss-making for four straight years from 2022 to 2025.

The operating margin improved from -46.4% in 2022 to -45.5% in 2023, -37.0% in 2024 and -27.1% in 2025. The company attributed the 2025 narrowing to higher export sales from overseas orders and greater sales to the Public Procurement Service, and to the base effect of unusual non-operating expenses in the prior year.

Net profit attributable to controlling shareholders was KRW 2.7 billion in 2022, swung to a net loss of KRW 2.86 billion in 2023, widened to a net loss of KRW 7.95 billion in 2024 and narrowed to a net loss of KRW 3.3 billion in 2025, which makes three straight years of losses from 2023 to 2025.

Net income including non-controlling interests is a different figure, a net loss of KRW 3.33 billion in 2025, so the two should be read separately. The debt-to-equity ratio rose from 91.6% in 2022 to 159.0% in 2023 and 675.6% in 2024, then fell to 257.5% in 2025.

Equity had shrunk to about KRW 3.0 billion by the end of 2024, which explains the 2024 ratio, and at the end of 2025 total equity was KRW 13.5 billion, equity attributable to controlling shareholders was KRW 15.3 billion and total liabilities were KRW 34.9 billion.

Operating cash flow was -KRW 8.59 billion in 2022, KRW 315 million in 2023 (a brief positive year), -KRW 4.09 billion in 2024 and -KRW 1.32 billion in 2025.

On a quarterly basis, Q4 2025 revenue was KRW 2.97 billion (down 18.2% from the prior quarter), and Q3 2026 revenue rose to KRW 7.15 billion (up 146.3% quarter on quarter and 97.3% year on year). Q3 2026 operating loss was KRW 1.16 billion, narrower than the KRW 1.94 billion in Q2 2026.

Q4 2025 posted an operating profit of KRW 346 million but a net profit attributable to controlling shareholders of KRW 6.95 billion; the reason that figure far exceeds operating profit cannot be pinned down from the disclosed numbers and is a point to check in the footnotes of the periodic report.

Over the four quarters from Q4 2025 to Q3 2026, net losses attributable to controlling shareholders totaled KRW 681 million. WiseReport data put the first-half 2026 revenue down 5.2% year on year and the operating loss up 43.6%.

Whether the Q3 revenue surge is one-off or recurring should be checked against the revenue breakdown in the next periodic report.

05

Industry analysis

Demand for animal medicines is tied to disease control that affects livestock productivity. WiseReport notes that demand for immune enhancers and antibiotic alternatives is rising, but roughly 1,100 domestic companies compete, which limits sales growth.

Moves to reduce antibiotic dependence put antibody technology forward as an alternative. The avian influenza antibodies under development are drawing attention as a complement to vaccines, given recurring outbreaks in poultry.

A March 2026 media report said the company confirmed the efficacy of an antibody therapy against highly mutating AI viruses. Growth in companion animal demand underpins the pet healthcare expansion, and the company is pursuing a lineup of therapeutics and functional supplements for dogs and cats.

In cyclical terms, demand moves with the frequency of disease outbreaks, so revenue volatility can be large. Large Korean biopharma names such as Samsung Biologics and Celltrion focus on CDMO and biosimilars, so their business structures differ from an animal antibody platform.

Comparisons with larger listed bio companies therefore start from differences in business model rather than market size.

06

Outlook

The company's emphasis is on broadening business purposes rather than on numerical targets. The purposes approved at the 2026 shareholder meeting include medical and pharmaceutical R&D, contract manufacturing, non-clinical and clinical consulting, and pet healthcare.

The joint development with U.S. biotech partner Exicure targets multiple indications, including solid tumors, sickle cell disease and acute myeloid leukemia, with a CXCR4 antagonist (burixafor) as the base.

Adbiotech is responsible for in vivo animal studies, preclinical validation and biomarker development in that project. Coverage noted that the venture could strengthen growth momentum if it advances to clinical stages, while stressing that it remains preclinical and early.

Proceeds from the rights issue, with KRW 13.26 billion received in August 2026, are planned for acquiring securities of other companies and for working capital.

A KRW 3.0 billion tenth convertible bond issued around the same time has a payment date set for August 31, 2026, and is subscribed by the largest shareholder's investment partnership. The Onheal stake is described by the company as a way to build synergies with non-clinical CRO and veterinary hospital platforms.

The company received a clean audit opinion on its 2025 financial statements and submitted the audit report on March 23, 2026. The next periodic report to check is the 2026 annual report, with a statutory filing deadline of March 31, 2027.

That report should be read together with the trend in operating loss margin, whether the Q3 2026 revenue surge persists, and changes in the debt ratio and cash flow.

07

Valuation

PER
—
PBR
—
ROE
-3.8%
EPS
-₩29
BPS
—
Dividend per share
₩0

Valuation is best read by considering earnings trends together with the capital structure. Net losses attributable to controlling shareholders over the four quarters from Q4 2025 to Q3 2026 totaled KRW 681 million, so the price-to-earnings ratio cannot be calculated on those figures.

The company pays no dividend, so there is effectively no cash return to shareholders. Market capitalization sits above the KRW 15.3 billion of equity attributable to controlling shareholders at the end of 2025, meaning the stock trades at a premium to book net assets.

Total equity recovered from about KRW 3.0 billion at the end of 2024 to KRW 13.5 billion at the end of 2025, which shows how much capital raising has driven book value. The 2026 rights issue and convertible bonds can increase the share count, so value per share will move with changes in equity and net earnings.

Because multiples move with the share price, comparisons are best framed alongside the trend in net assets and net earnings.

PER, EPS, PBR and BPS are all calculated in-house (the same method as Naver and Toss) · Dividend yield = cash dividend per share from DART filings (supplemented by KRX) ÷ current price · As of 2026-11-18

08

Bull factors

Two years of revenue growth and a Q3 surge

Revenue reached KRW 12.9 billion in 2025, up 15.8% from 2024, marking a second consecutive annual increase. Q3 2026 revenue of KRW 7.15 billion was up 97.3% year on year, a sign of quarterly recovery. The company credited export sales from overseas orders and Public Procurement Service sales for the 2025 gain. Whether the Q3 increase is one-off or recurring will need to be checked in the periodic report.

A steady narrowing of the operating loss

The operating loss narrowed each year from KRW 4.94 billion in 2022 to KRW 3.5 billion in 2025. The operating margin improved from -46.4% to -27.1% over the same period. The Q3 2026 operating loss of KRW 1.16 billion was smaller than the KRW 1.94 billion recorded in Q2 2026.

Optionality in bio R&D and pet healthcare

In the joint development with Exicure, Adbiotech is responsible for in vivo research, preclinical validation and biomarker development. Acquiring a 12.28% stake in Onheal is described by the company as a source of synergy with pet CRO and veterinary hospital platforms. The antibody platform's extension into avian influenza antibodies and pet products is also cited as a strength.

09

Bear factors

Three straight loss quarters and a wider first-half loss

The company recorded operating losses for three consecutive quarters from Q1 to Q3 2026. WiseReport data show first-half 2026 operating loss widened 43.6% year on year while revenue fell 5.2%. Net losses attributable to controlling shareholders also ran for three consecutive quarters from Q1 to Q3 2026.

Reliance on capital raising and dilution

The August 2026 rights issue added 7.27 million new shares, and a KRW 3.0 billion convertible bond was issued to the largest shareholder's fund around the same time. Part of the ninth convertible bond, KRW 1.9 billion of a KRW 3.75 billion face value, was bought back before maturity using cash.

The debt-to-equity ratio fell from 675.6% in 2024 to 257.5% in 2025, but liabilities remain large relative to equity.

Execution risk in the expansion

The business purposes now span medical and pharmaceutical R&D, contract manufacturing, clinical consulting and pet funeral services. The Exicure joint development remains at an early, preclinical stage.

With roughly 1,100 domestic companies competing in animal medicines, focusing on new businesses could dilute attention on the core franchise.

10

Risk factors

Balance sheet and liquidity

Total liabilities at the end of 2025 were KRW 34.9 billion, above total equity of KRW 13.5 billion. Operating cash flow was negative in 2022, 2024 and 2025, with only a brief positive year in 2023. Until cash generation improves, reliance on external funding through share issues and convertible bonds may continue.

Dilution and governance

After the rights issue, the largest shareholder's investment partnership holds about 34.86%. Four new directors, including internal and independent directors, were approved at the August 2026 shareholder meeting, reshaping the board.

Conversion of the convertible bonds would increase the share count, so conversion terms and governance changes need ongoing monitoring through disclosures.

Business, competition and clinical

Competition in animal medicines is intense, with roughly 1,100 domestic companies. The new businesses are at early stages such as preclinical research and consulting. Revenue can swing with livestock disease patterns, so whether the Q3 2026 surge persists will be a key driver of the earnings trend.

11

What to watch next

  1. Around February 2027

    2026 annual results. The 2025 annual results were disclosed on February 9, 2026. Check whether Q4 2026 operating results turn positive and whether the Q3 revenue surge carries into the full-year figures.

  2. March 31, 2027

    Filing deadline for the 2026 annual report. This is the next periodic report, where the operating loss margin, net loss attributable to controlling shareholders, debt-to-equity ratio, operating cash flow and revenue breakdown should be checked.

  3. May 15, 2027

    Filing deadline for the Q1 2027 quarterly report, 45 days after quarter end. Check the progress of the Exicure joint development and whether pet healthcare sales are contributing to revenue.

  4. Timing undetermined (depends on disclosure)

    Preclinical results from the Exicure joint development and whether it advances to clinical stages. The nature of the business value depends on whether that progression occurs.

12

Overall view

Adbiotech is narrowing its losses, with 2025 revenue of KRW 12.9 billion rising for a second straight year and the operating loss falling to KRW 3.5 billion.

However, operating losses have run for four straight years from 2022 and net losses attributable to controlling shareholders for three straight years from 2023, so an earnings recovery is not yet established.

The Q3 2026 revenue of KRW 7.15 billion and operating loss of KRW 1.16 billion are encouraging, but operating losses have persisted for three straight quarters from Q1 2026 and the first-half operating loss widened year on year.

The debt-to-equity ratio fell from 675.6% in 2024 to 257.5% in 2025, yet rights issues and a convertible bond sold to the largest shareholder mean the share count and capital structure will keep changing.

Antibody-based animal medicines and feed supplements account for roughly 80% of revenue, and the 2026 business purposes have widened into bio R&D and pet healthcare. The Exicure joint development and the Onheal stake are growth options, but the former is preclinical and neither is yet reflected in reported results.

Strengths include the revenue recovery and narrower losses, while weaknesses include persistent losses, reliance on capital raising and execution risk in new businesses. The next checkpoint is the operating loss margin and revenue breakdown in the 2026 annual report.

13

Sources

  1. Korea Exchange (KRX) — Prices · Market Cap · Volume
  2. FSS electronic disclosure system (DART) — Financial statements · Dividend filings
Show 17 more articles and sources
  1. comp.wisereport.co.kr
  2. mt.co.kr
  3. etoday.co.kr
  4. mt.co.kr
  5. sedaily.com
  6. etoday.co.kr
  7. biotimes.co.kr
  8. view.asiae.co.kr
  9. dealsite.co.kr
  10. etoday.co.kr
  11. news.nate.com
  12. butler.works
  13. dailyan.com
  14. judal.co.kr
  15. view.asiae.co.kr
  16. m.news.nate.com
  17. m.news.nate.com

Report written 2026-11-18 · Data as of 2026-11-17

This content is AI analysis of market data and web search results, provided for information only. It is not a solicitation or recommendation to invest. Investment decisions and their consequences are the investor's own responsibility. Data may be delayed or contain errors.

Other reports in this industry

View industry analysis